Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

295 results about "Antigen presentation" patented technology

Antigen presentation describes a vital immune process which is essential for T cell immune response triggering. Because T cells recognise only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment, now bound to the major histocompatibility complex (MHC), is transported to the surface of the cell, a process known as presentation, where it can be recognized by a T cell receptor. If there has been an infection with viruses or bacteria, the cell will present an endogenous or exogenous peptide fragment derived from the antigen bound to MHC molecules. There are two types of MHC molecules which differ in the of the antigens: MHC class I molecules (MHC-I) bind peptides from the cell cytosol, while peptides generated in the endocytic vesicles after internalisation are bound to MHC class II (MHC-II). Cellular membranes separate these two cellular environments - intracellular and extracellular. Each T cell can finally recognise only ten to hundreds copies of a unique sequence of a single peptide among thousands of other peptides presented on the very same cell because MHC molecule in one cell can bind quite a large range of peptides.

Nanoparticles for immunotherapy

Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Programmed immune responses using a vaccination node

The present invention provides compositions and methods for modulating immune responses to antigens. One aspect of the present invention relates to a particle-based antigen delivery system (vaccination node) that comprises a hydrogel particle capable of both antigen presentation and DC activation. The VN may further comprise a chemoattractant-loaded microsphere capable of attracting DCs to the site of administration. Another aspect of the present invention relates to the use of the VN to modulate antigen presenting cells activation for the prevention and / treatment of various diseases, such as infectious diseases, cancers and autoimmune diseases.
Owner:VAXDESIGN

Modulation of negative immune regulators and applications for immunotherapy

The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.
Owner:BAYLOR COLLEGE OF MEDICINE

Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells

The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
Owner:BAYLOR RES INST

Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells

Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity.
Owner:ALEXION PHARMA INC

CD47 and PD-L1 targeting bifunctional fusion protein

The invention relates to a CD47 and PD-L1 targeting bifunctional fusion protein, belongs to the field of biomedicine, and solves the problems that anti-PD-1 / PD-L1 treatment is poor in a low-immunogenicity tumor treatment effect and anti-CD47 treatment is poor in a targeting ability. The fusion protein is composed of a CD47 binding part and a PD-L1 binding part which are linked by a disulfide bond, can block the binding of CD47 and SIRPalpha, can block the binding of PD-L1 and PD-1, can achieve the effects of activating macrophages to phagocytize tumor cells and promoting antigen presentation in natural immunity, can achieve an effect of promoting the activation of tumor specific T cells in acquired immunity, and has lower blood toxicity; and as compared with the single use of anti-PD-L1 or anti-CD47 for treatment, the fusion protein has better antitumor curative effects and blood safety.
Owner:TAIZHOU MABTECH PHARM CO LTD

Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells

This invention relates to methods of using human dendritic cells to present antigens for the induction of antigen-specific T cell-mediated immune responses. In particular, it relates to the isolation of dendritic cells from human blood, exposing the cells to antigens, co-culturing the antigen-pulsed dendritic cells with gammadelta-T cell receptor-positive-T cells (gammadelta-TCR<+> T cells) obtained from unprimed or weakly primed individuals for the stimulation of antigen-specific T cell proliferative and cytotoxic activities. The dendritic cell antigen presentation system described herein has a wide range of applications, including but not limited to, activation and expansion of large numbers of antigen-specific major histocompatibility complex-unrestricted T cells for use in adoptive cellular immunotherapy against infectious diseases and cancer.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment

A statistical and functional correlation strategy to identify changes in cellular pathways specifically linked to impaired cognitive function with aging. Analyses using the strategy identified multiple groups of genes expressed in the hippocampi of mammals, where the genes were expressed at different levels for several ages. The aging changes in expression began before mid-life. Many of the genes were involved in specific neuronal and glial pathways with previously unrecognized relationships to aging and / or cognitive decline. The processes identified by the strategy suggest a new hypothesis of brain aging in which initially decreased neuronal activity and / or oxidative metabolism trigger separate but parallel genomic cascades in neurons and glia. In neurons, the cascade results in elevations in calcium signaling and reductions of immediate early gene signaling, biosynthesis, synaptogenesis and neurite remodeling. In contrast, glia undergo increased lipid metabolism and mediate a cycle of demyelination and remyelination that induces antigen presentation, inflammation, oxidative stress and extracellular restructuring. These identified genes and the proteins they encode can be used as novel biomarkers of brain aging and as targets for developing treatment methods against age-related cognitive decline, Alzheimer's Disease and Parkinson's Disease.
Owner:UNIV OF KENTUCKY RES FOUND

Superior molecular vaccine based on self-replicating RNA, suicidal DNA or naked DNA vector, that links antigen with polypeptide that promotes antigen presentation

Improved molecular vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide physically linked to an antigen. The linked polypeptide is one that (a) promotes processing of the expressed fusion polypeptide via the MHC class I pathway and / or (b) promotes development or activity of antigen presenting cells, primarily dendritic cells. These vaccines employ one of several types of nucleic acid vectors, each with its own relative advantages: naked DNA plasmids, self-replicating RNA replicons and suicidal DNA-based on viral RNA replicons. Administration of such a vaccine results in enhance immune responses, primarily those mediated by CD8+ cytotoxic T lymphocytes, directed against the immunizing antigen part of the fusion polypeptide. Such vaccines are useful against tumor antigens, viral antigens and antigens of other pathogenic microorganisms and can be used in the prevention or treatment of diseases that include cancer and infections.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Adjuvant for transcutaneous immunization

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.
Owner:UNITED STATES OF AMERICA

Presentation of hydrophobic antigens to T-cells by CD1 molecules

Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including:methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample;methods for isolating such CD1-presented antigens and the isolated antigens;vaccines containing CD1-presented antigens and vaccination methods;methods of blocking CD1 antigen presentation;methods of identifying and / or isolating CD1 blocking agents and the isolated CD1 blocking agents;methods of inducing CD1 expression; andT-cells for use in the methods disclosed.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells

The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
Owner:BAYLOR RES INST

Modulation of cytokine signaling regulators and applications for immunotherapy

The present invention relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS (SOCS1-7, CIS), SHP (SHP-1 and SHP-2) or PIAS (PIAS1, PIAS3, PIASx and PIASy). The present invention provides vaccines and therapies in which antigen presentation is enhanced through modulation of cytokine signaling regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.
Owner:BAYLOR COLLEGE OF MEDICINE

Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells

Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity.
Owner:ALEXION PHARMA INC

Use of polymeric nanoparticles for vaccine delivery

The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a polymeric nanoparticle containing a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary peptide utilized in the invention is Mart-1:27-35 peptide.
Owner:RGT UNIV OF CALIFORNIA

Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation

InactiveUS20050277605A1Great E7-specific T cell-mediated immunityEfficiently presentedSsRNA viruses positive-senseAntibody mimetics/scaffoldsMHC class IDisease
Improved molecular vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide physically linked to an antigen. The linked polypeptide is one that (a) promotes processing of the expressed fusion polypeptide via the MHC class I pathway and / or (b) promotes development or activity of antigen presenting cells, primarily dendritic cells. These vaccines employ one of several types of nucleic acid vectors, each with its own relative advantages: naked DNA plasmids, self-replicating RNA replicons and suicidal DNA-based on viral RNA replicons. Administration of such a vaccine results in enhance immune responses, primarily those mediated by CD8+ cytotoxic T lymphocytes, directed against the immunizing antigen part of the fusion polypeptide. Such vaccines are useful against tumor antigens, viral antigens and antigens of other pathogenic microorganisms and can be used in the prevention or treatment of diseases that include cancer and infections.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction

Methods of using inhibitors of the CD2 / LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
Owner:ASTELLAS US

Advanced antigen presentation platform

The present invention provides particles for the presentation of haptens for the purpose of eliciting an immune response. The amino acid sequences of the monomers which make up the particles are derived from duck hepatitis B virus core protein. The particles may also deliver nucleic acids. The nucleic acids may be delivered for the purpose of enhancing an immune response, or for other purposes such as gene therapy.
Owner:BIOCACHE PHARMA +1

Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells

The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
Owner:BAYLOR RES INST

Enhancing Class I Antigen Presentation With Synthetic Sequences

The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary antigen utilized in the invention is HER2 / neu. The peptides peptide vaccines of the invention are derived from the antigens PRAME, OFA / iLRP, STEAP and SURVIVIN.
Owner:RGT UNIV OF CALIFORNIA

Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials

Methods are provided for producing functional antigen presenting dendritic cells. The dendritic cells are produced by treating an extracorporeal quantity of a subject's blood to induce differentiation of blood monocytes into dendritic cells. The dendritic cells may be exposed to cellular material encapsulated within a biodegradable polymer material to produce the antigen presenting dendritic cells.
Owner:EDELSON RICHARD L +3

Methods of enhancing the immunogenicity of mycobacteria and compositions for the treatment of cancer, tuberculosis, and fibrosing lung diseases

InactiveUS20110243992A1Enhance recruitmentIncreased activationAntibacterial agentsBacteriaMycobacterium immunogenumCancer cell
Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.
Owner:VANDERBILT UNIV

DC cell membrane bionic liposome drug carrier as well as preparation method and application thereof

The invention relates to a targeting personalized DC cell membrane bionic liposome drug carrier as well as a preparation method and application thereof. The DC cell membrane bionic liposome drug carrier is characterized in that (1) the liposome drug carrier has a cell membrane protein component; (2) the liposome drug carrier can carry a drug in vitro and is used for cell targeting fused release; and (3) the cell membrane protein component of the liposome comes from immortalized somatic cells. The invention has the following advantages: the drug carrier can be applied to the targeting delivery to in-vivo DC cells of a drug or antigen, the antigen presentation ability of the DC cells is enhanced, and the specific immunity is improved.
Owner:李因传

Polymer nano carrier preparation as well as preparation method and application thereof

The invention relates to a polymer nano carrier preparation as well as a preparation method and an application thereof. The nano carrier preparation employs a nano carrier micelle of a three-layer structure to carry DNA (Deoxyribonucleic Acid) antigen, protein antigen, polypeptide antigen and immunologic adjuvant. The polymer nano carrier preparation is good in stability and immunogenicity, and can not only prompt ingestion of antigen presentation cells such as dendritic cells for the antigen, but also remarkably induce organisms to make specific immune response.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods

The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and / or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and / or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.
Owner:KAY HEIDI

Hydrophobic Modified Pres-Derived Peptides of Hepatitis B Virus (HBV) and Their Use as Vehicles for the Specific Delivery of Compounds to the Liver

The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are versatile vehicles for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. Any kind of compound, but in particular drugs, such as interferons, viral reverse transcriptase inhibitors or core assembly inhibitors, and / or labels can be specifically targeted to the liver and so be enriched in the liver. This liver targeting can further be used for the targeted diagnosis, prevention and / or treatment of liver diseases or disorders, such as hepatitis, malaria, hepatocellular carcinoma (HCC), as well as for the prevention of HAV, HBV, HCV and / or HDV infection. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified preS-derived peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to a method for the combined treatment of a liver disease and the prevention of HAV, HBV, HCV and / or HDV infection. The present invention relates also to the use of the preS-derived peptides in gene therapy and the delivery of immunogenic epitopes for hepatocyte-mediated antigen presentation to activate liver-directed immunological responses.
Owner:UNIVERSITY OF HEIDELBERG

Synthesis method of high-sensitivity carbendazol complete antigen

The invention relates to a synthesis method of a high-sensitivity carbendazol complete antigen, belonging to the technical field of biochemical engineering. In the method, a carboxylic hapten H1 is synthesized by reacting carbendazol analog 2-chlorobenzimidazole and 6-aminocaproic acid, and is coupled with a carrier protein to prepare an immunogen; and on the basis that the heterologous coating can further enhance the sensitivity of the antibody, the hapten H2 obtained by reacting the carbendazol analog aminochlorobenzimidazole and 6-aminocaproic acid is coupled with OVA to obtain the coupled substance which can be used as a coating source. The complete antigen prepared by the method appears a specific carbendazol antigenic determinant, thereby providing possibilities for screening out high-specificity carbendazol monoclonal antibodies. The generated antibody has the advantages of high specificity and high sensitivity, and can be used for establishing an enzyme linked immunosorbent assay analysis method and a colloidal gold test paper quick detection method, thereby being used for quickly detecting carbendazol residues in food.
Owner:JIANGNAN UNIV

Nucleotide sequence for encoding novel coronavirus antigen and application of nucleotide sequence

The invention provides a nucleotide sequence for encoding a novel coronavirus antigen and application of the nucleotide sequence. According to the nucleotide sequence, a wild-type DNA sequence for encoding SARS-CoV-2 virus surface protein Spike is optimized, a wild-type gene signal peptide is optimized and then inserted into an eukaryotic expression vector, the eukaryotic expression vector is introduced into a host cell, a virus Spike antigen is efficiently expressed in the host cell, and an antiviral humoral immune response and a cellular immune response are systematically activated after antigen presentation. The antibody generated by the activated humoral immune response can prevent invasion of the SARS-CoV-2 virus, and the activated cellular immune response can further remove cells infected by the virus and adjust adverse reactions caused by potential side effects of ADE.
Owner:ADVACCINE SUZHOU BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products